HilleVax, Inc. Stock price

Equities

HLVX

US43157M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
17.19 USD -1.26% Intraday chart for HilleVax, Inc. +14.68% +7.10%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * - Sales 2024 * - Capitalization 800M
Net income 2023 * -126M Net income 2024 * -170M EV / Sales 2023 * -
Net cash position 2023 * 271M Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-5.59 x
P/E ratio 2024 *
-5.3 x
Employees 62
Yield 2023 *
-
Yield 2024 *
-
Free-Float 89.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.26%
1 week+14.68%
Current month+21.31%
1 month+11.99%
3 months+23.31%
6 months+36.10%
Current year+7.10%
More quotes
1 week
15.01
Extreme 15.01
18.00
1 month
13.86
Extreme 13.855
18.00
Current year
13.86
Extreme 13.855
18.00
1 year
9.94
Extreme 9.94
19.09
3 years
7.90
Extreme 7.9
24.42
5 years
7.90
Extreme 7.9
24.42
10 years
7.90
Extreme 7.9
24.42
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 20-02-29
Director of Finance/CFO 42 21-11-30
Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Chief Executive Officer 61 20-02-29
Director/Board Member 66 21-03-31
Director/Board Member 54 21-07-31
More insiders
Date Price Change Volume
24-02-28 17.19 -1.26% 54,679
24-02-27 17.41 +2.23% 64,638
24-02-26 17.03 +7.65% 98,165
24-02-23 15.82 +5.12% 303,184
24-02-22 15.05 +0.40% 187,319

Delayed Quote Nasdaq, February 28, 2024 at 04:00 pm EST

More quotes
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.19 USD
Average target price
28.2 USD
Spread / Average Target
+64.05%
Consensus
  1. Stock
  2. Equities
  3. Stock HilleVax, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW